Going-Private Merger Consideration Drastically Cut by 92.7% to $0.066 Per Share

summarizeSummary

LakeShore Biopharma has finalized an amended going-private merger agreement, slashing the per-share consideration for public shareholders from US$0.90 to US$0.066, a 92.7% reduction.

check_boxKey Events

• Merger Consideration Drastically Reduced

  The per-share merger consideration for the going-private transaction has been cut from US$0.90 to US$0.066, representing a 92.7% reduction for public shareholders.

• Amended Merger Agreements Detailed

  The filing provides the full legal terms of the Amendment No. 1 to the Agreement and Plan of Merger, along with amended and restated Equity Commitment Letter, Support Agreement, and Limited Guarantee.

• Rollover Shareholders Commit to New Entity

  Key shareholders, including Huaqin Xue and Crystal Peak, will cancel their shares for no cash consideration, receiving newly issued shares in the acquiring entity (Parent), collectively holding 53.35% of its voting rights.

• Equity Financing Secured

  Oceanpine Capital Inc. will provide US$1.27 million in equity financing to the Parent to consummate the transaction.

auto_awesomeAnalysis

This Schedule 13D/A provides the full legal details of the amended going-private merger agreement, confirming a severe reduction in the per-share consideration from US$0.90 to US$0.066. This represents a 92.7% decrease in the buyout price for public shareholders. While the company's stock is currently trading below the new offer price, the drastic cut from the original offer is a significant negative development, fundamentally altering the investment thesis for existing shareholders. The transaction, supported by rollover shareholders and new equity financing, aims to take the company private, removing its shares from the OTC Pink Open Market. This event signals a highly unfavorable outcome for public investors in the going-private transaction.